



LASERS

DYE-LASER 595NM COMBINED WITH FRACTIONAL CO2 LASER: A SUCCESSFUL THERAPEUTIC OPTION FOR THE TREATMENT OF SUPERFICIAL BASAL CELLS CARCINOMA.

Ester Del Duca⁽¹⁾ - Virginia Garofalo⁽¹⁾ - Cosimo Di Raimondo⁽¹⁾ - Sara Mazzilli⁽¹⁾ - Mario Sannino⁽¹⁾ - Giovanni Cannarozzo⁽¹⁾ - Luca Bianchi⁽¹⁾ - Steven Paul Nisticò⁽²⁾

Università Di Roma Tor Vergata, Dipartimento Di Dermatologia, Unità Di Laserterapia, Roma, Italy⁽¹⁾ - Università Degli Studi Di Catanzaro Magna Graecia, Dipartimento Di Dermatologia, Unità Di Laserterapia, Catanzaro, Italy⁽²⁾

Introduction: Basal cell carcinoma (BCC) is the most common skin malignancy and exposure to sunlight is the most important risk factor. There are many potential management strategies for BCCs but, due to their side effects, the choice of the therapy for each patient is not straightforward. CO₂ Laser is a well-known ablative laser used to treat several benign dermatological conditions. Dye-Laser 595nm has been used to treat vascular anomalies for about 30 years; however, many other possible fields of application remain unexplored.

Objective: Dye-Laser can specifically target and destroy the enlarged blood vessels that sustain tumoral tissue. This study aimed to investigate the safety and efficacy of Dye-Laser 595nm used as therapeutic option for the treatment of superficial BCCs when combined with a pretreatment section of fractional CO₂ laser.

Material and Methods: 20 patients (8 males), aged from 55 to 85 affected by superficial BCCs were enrolled in this study. Diagnosis of BCC and treatment efficacy were assessed by dermoscopy and documented by photographic records. Patients underwent 5 section of flash-pumped, 595nm Dye-Laser preceded by fractional CO₂ treatment for a total of 5 sections scheduled each 20 days. A 24 months follow-up was performed to assess the relapse rate.

Results: A complete response have been seen in 19 out of 20 patients. We also observed 3 clinical relapses after 16 months since the last laser section and only in one patient we observed lack of complete response. We reported no side effects.

Conclusions: our study shows the effectiveness of flash-pumped, 595nm Dye-Laser used in combination with fractional CO₂ laser for the treatment of superficial BCCs. The non-necessity of co-adjuvant therapies to achieve clinical clearance, the low rate of relapses and





the absence of side effect delineate the combined therapy Dye-Laser and Fractional CO₂ as a valid option for BBCs treatment.

